HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Identifieur interne : 000057 ( PubMed/Corpus ); précédent : 000056; suivant : 000058HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Auteurs : Nicholas I. Nii-Trebi ; Shiro Ibe ; Jacob S. Barnor ; Koichi Ishikawa ; James A M. Brandful ; Sampson B. Ofori ; Shoji Yamaoka ; William K. Ampofo ; Wataru SugiuraSource :
- PloS one [ 1932-6203 ] ; 2013.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (pharmacology), Anti-HIV Agents (therapeutic use), Benzoxazines (pharmacology), Benzoxazines (therapeutic use), Child, Child, Preschool, Drug Resistance, Viral, Epidemiological Monitoring, Female, Ghana (epidemiology), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV Infections (transmission), HIV Protease (genetics), HIV-1 (drug effects), HIV-1 (genetics), Humans, Infant, Lamivudine (pharmacology), Lamivudine (therapeutic use), Male, Middle Aged, Molecular Epidemiology, Molecular Typing, Mutation, Missense, Nevirapine (pharmacology), Nevirapine (therapeutic use), Prevalence, Sequence Analysis, DNA, Stavudine (pharmacology), Stavudine (therapeutic use), Zidovudine (pharmacology), Zidovudine (therapeutic use).
- MESH :
- chemical , genetics : HIV Protease.
- chemical , pharmacology : Anti-HIV Agents, Benzoxazines, Lamivudine, Nevirapine, Stavudine, Zidovudine.
- chemical , therapeutic use : Anti-HIV Agents, Benzoxazines, Lamivudine, Nevirapine, Stavudine, Zidovudine.
- geographic , epidemiology : Ghana.
- drug effects : HIV-1.
- drug therapy : HIV Infections.
- epidemiology : HIV Infections.
- genetics : HIV-1.
- transmission : HIV Infections.
- Adult, Child, Child, Preschool, Drug Resistance, Viral, Epidemiological Monitoring, Female, Humans, Infant, Male, Middle Aged, Molecular Epidemiology, Molecular Typing, Mutation, Missense, Prevalence, Sequence Analysis, DNA.
Abstract
Limited HIV-1 drug-resistance surveillance has been carried out in Ghana since the implementation of antiretroviral therapy (ART). This study sought to provide data on the profile of HIV-1 drug resistance in ART-experienced and newly diagnosed individuals in Ghana.
DOI: 10.1371/journal.pone.0071972
PubMed: 23977189
Links to Exploration step
pubmed:23977189Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.</title><author><name sortKey="Nii Trebi, Nicholas I" sort="Nii Trebi, Nicholas I" uniqKey="Nii Trebi N" first="Nicholas I" last="Nii-Trebi">Nicholas I. Nii-Trebi</name><affiliation><nlm:affiliation>Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Ghana, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Ibe, Shiro" sort="Ibe, Shiro" uniqKey="Ibe S" first="Shiro" last="Ibe">Shiro Ibe</name></author><author><name sortKey="Barnor, Jacob S" sort="Barnor, Jacob S" uniqKey="Barnor J" first="Jacob S" last="Barnor">Jacob S. Barnor</name></author><author><name sortKey="Ishikawa, Koichi" sort="Ishikawa, Koichi" uniqKey="Ishikawa K" first="Koichi" last="Ishikawa">Koichi Ishikawa</name></author><author><name sortKey="Brandful, James A M" sort="Brandful, James A M" uniqKey="Brandful J" first="James A M" last="Brandful">James A M. Brandful</name></author><author><name sortKey="Ofori, Sampson B" sort="Ofori, Sampson B" uniqKey="Ofori S" first="Sampson B" last="Ofori">Sampson B. Ofori</name></author><author><name sortKey="Yamaoka, Shoji" sort="Yamaoka, Shoji" uniqKey="Yamaoka S" first="Shoji" last="Yamaoka">Shoji Yamaoka</name></author><author><name sortKey="Ampofo, William K" sort="Ampofo, William K" uniqKey="Ampofo W" first="William K" last="Ampofo">William K. Ampofo</name></author><author><name sortKey="Sugiura, Wataru" sort="Sugiura, Wataru" uniqKey="Sugiura W" first="Wataru" last="Sugiura">Wataru Sugiura</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23977189</idno><idno type="pmid">23977189</idno><idno type="doi">10.1371/journal.pone.0071972</idno><idno type="wicri:Area/PubMed/Corpus">000057</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000057</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.</title><author><name sortKey="Nii Trebi, Nicholas I" sort="Nii Trebi, Nicholas I" uniqKey="Nii Trebi N" first="Nicholas I" last="Nii-Trebi">Nicholas I. Nii-Trebi</name><affiliation><nlm:affiliation>Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Ghana, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Ibe, Shiro" sort="Ibe, Shiro" uniqKey="Ibe S" first="Shiro" last="Ibe">Shiro Ibe</name></author><author><name sortKey="Barnor, Jacob S" sort="Barnor, Jacob S" uniqKey="Barnor J" first="Jacob S" last="Barnor">Jacob S. Barnor</name></author><author><name sortKey="Ishikawa, Koichi" sort="Ishikawa, Koichi" uniqKey="Ishikawa K" first="Koichi" last="Ishikawa">Koichi Ishikawa</name></author><author><name sortKey="Brandful, James A M" sort="Brandful, James A M" uniqKey="Brandful J" first="James A M" last="Brandful">James A M. Brandful</name></author><author><name sortKey="Ofori, Sampson B" sort="Ofori, Sampson B" uniqKey="Ofori S" first="Sampson B" last="Ofori">Sampson B. Ofori</name></author><author><name sortKey="Yamaoka, Shoji" sort="Yamaoka, Shoji" uniqKey="Yamaoka S" first="Shoji" last="Yamaoka">Shoji Yamaoka</name></author><author><name sortKey="Ampofo, William K" sort="Ampofo, William K" uniqKey="Ampofo W" first="William K" last="Ampofo">William K. Ampofo</name></author><author><name sortKey="Sugiura, Wataru" sort="Sugiura, Wataru" uniqKey="Sugiura W" first="Wataru" last="Sugiura">Wataru Sugiura</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (pharmacology)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Benzoxazines (pharmacology)</term><term>Benzoxazines (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Drug Resistance, Viral</term><term>Epidemiological Monitoring</term><term>Female</term><term>Ghana (epidemiology)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (transmission)</term><term>HIV Protease (genetics)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>Humans</term><term>Infant</term><term>Lamivudine (pharmacology)</term><term>Lamivudine (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Molecular Epidemiology</term><term>Molecular Typing</term><term>Mutation, Missense</term><term>Nevirapine (pharmacology)</term><term>Nevirapine (therapeutic use)</term><term>Prevalence</term><term>Sequence Analysis, DNA</term><term>Stavudine (pharmacology)</term><term>Stavudine (therapeutic use)</term><term>Zidovudine (pharmacology)</term><term>Zidovudine (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>HIV Protease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>Benzoxazines</term><term>Lamivudine</term><term>Nevirapine</term><term>Stavudine</term><term>Zidovudine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Benzoxazines</term><term>Lamivudine</term><term>Nevirapine</term><term>Stavudine</term><term>Zidovudine</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Child</term><term>Child, Preschool</term><term>Drug Resistance, Viral</term><term>Epidemiological Monitoring</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Molecular Epidemiology</term><term>Molecular Typing</term><term>Mutation, Missense</term><term>Prevalence</term><term>Sequence Analysis, DNA</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Limited HIV-1 drug-resistance surveillance has been carried out in Ghana since the implementation of antiretroviral therapy (ART). This study sought to provide data on the profile of HIV-1 drug resistance in ART-experienced and newly diagnosed individuals in Ghana.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23977189</PMID><DateCreated><Year>2013</Year><Month>08</Month><Day>26</Day></DateCreated><DateCompleted><Year>2014</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>8</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.</ArticleTitle><Pagination><MedlinePgn>e71972</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0071972</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Limited HIV-1 drug-resistance surveillance has been carried out in Ghana since the implementation of antiretroviral therapy (ART). This study sought to provide data on the profile of HIV-1 drug resistance in ART-experienced and newly diagnosed individuals in Ghana.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Samples were collected from 101 HIV-1-infected patients (32 ART-experienced cases with virological failure and 69 newly diagnosed ART-naïve cases, including 11 children), in Koforidua, Eastern region of Ghana, from February 2009 to January 2010. The pol gene sequences were analyzed by in-house HIV-1 drug-resistance testing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The most prevalent HIV-1 subtype was CRF02_AG (66.3%, 67/101) followed by unique recombinant forms (25.7%, 26/101). Among 31 ART-experienced adults, 22 (71.0%) possessed at least one drug-resistance mutation, and 14 (45.2%) had two-class-resistance to nucleoside and non-nucleoside reverse-transcriptase inhibitors used in their first ART regimen. Importantly, the number of accumulated mutations clearly correlated with the duration of ART. The most prevalent mutation was lamivudine-resistance M184V (n = 12, 38.7%) followed by efavirenz/nevirapine-resistance K103N (n = 9, 29.0%), and zidovudine/stavudine-resistance T215Y/F (n = 6, 19.4%). Within the viral protease, the major nelfinavir-resistance mutation L90M was found in one case. No transmitted HIV-1 drug-resistance mutation was found in 59 ART-naïve adults, but K103N and G190S mutations were observed in one ART-naïve child.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite expanding accessibility to ART in Eastern Ghana, the prevalence of transmitted HIV-1 drug resistance presently appears to be low. As ART provision with limited options is scaled up nationwide in Ghana, careful monitoring of transmitted HIV-1 drug resistance is necessary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nii-Trebi</LastName><ForeName>Nicholas I</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibe</LastName><ForeName>Shiro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Barnor</LastName><ForeName>Jacob S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Brandful</LastName><ForeName>James A M</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Ofori</LastName><ForeName>Sampson B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Yamaoka</LastName><ForeName>Shoji</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ampofo</LastName><ForeName>William K</ForeName><Initials>WK</Initials></Author><Author ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Wataru</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2T8Q726O95</RegistryNumber><NameOfSubstance UI="D019259">Lamivudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>99DK7FVK1H</RegistryNumber><NameOfSubstance UI="D019829">Nevirapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>BO9LE4QFZF</RegistryNumber><NameOfSubstance UI="D018119">Stavudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016333">HIV Protease</NameOfSubstance></Chemical><Chemical><RegistryNumber>JE6H2O27P8</RegistryNumber><NameOfSubstance UI="C098320">efavirenz</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010;5(6):e10952</RefSource><PMID Version="1">20532178</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ghana Med J. 2009 Dec;43(4):142-3</RefSource><PMID Version="1">21326992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2003 Oct 1;188(7):992-1000</RefSource><PMID Version="1">14513419</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2006 Feb;22(2):182-7</RefSource><PMID Version="1">16478401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2011 Aug;49(8):2859-67</RefSource><PMID Version="1">21697329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2009;4(3):e4724</RefSource><PMID Version="1">19266092</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Biol Evol. 2011 Oct;28(10):2731-9</RefSource><PMID Version="1">21546353</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Rev. 2012 Jan-Mar;14(1):17-27</RefSource><PMID Version="1">22297501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2007 Feb;45(2):477-87</RefSource><PMID Version="1">17182760</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2004 Nov;78(22):12438-45</RefSource><PMID Version="1">15507630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Top Antivir Med. 2011 Nov;19(4):156-64</RefSource><PMID Version="1">22156218</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):599-606</RefSource><PMID Version="1">18645511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2004 Jun;73(2):158-66</RefSource><PMID Version="1">15122787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 1999 Jan;73(1):152-60</RefSource><PMID Version="1">9847317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2010 Dec;26(12):1291-8</RefSource><PMID Version="1">20954840</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2007 Oct;40(2):163-7</RefSource><PMID Version="1">17827059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2010 Mar;10(3):155-66</RefSource><PMID Version="1">20185094</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genome Res. 2007 Aug;17(8):1195-201</RefSource><PMID Version="1">17600086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2009 Mar 1;199(5):693-701</RefSource><PMID Version="1">19210162</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062665" MajorTopicYN="N">Epidemiological Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016333" MajorTopicYN="N">HIV Protease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019259" MajorTopicYN="N">Lamivudine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017720" MajorTopicYN="N">Molecular Epidemiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058889" MajorTopicYN="N">Molecular Typing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019829" MajorTopicYN="N">Nevirapine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018119" MajorTopicYN="N">Stavudine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015215" MajorTopicYN="N">Zidovudine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3747072</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>04</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23977189</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0071972</ArticleId><ArticleId IdType="pii">PONE-D-13-14356</ArticleId><ArticleId IdType="pmc">PMC3747072</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000057 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000057 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23977189
|texte= HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23977189" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |